- Home
- LZB vs JANX Comparison
LZB vs JANX Comparison
Compare LZB & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- JANX
- Stock Information
- Founded
- LZB 1927
- JANX 2017
- Country
- LZB United States
- JANX United States
- Employees
- LZB N/A
- JANX N/A
- Industry
- LZB Home Furnishings
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- LZB Consumer Discretionary
- JANX Health Care
- Exchange
- LZB Nasdaq
- JANX Nasdaq
- Market Cap
- LZB 1.6B
- JANX 1.4B
- IPO Year
- LZB N/A
- JANX 2021
- Fundamental
- Price
- LZB $38.67
- JANX $25.11
- Analyst Decision
- LZB Buy
- JANX Strong Buy
- Analyst Count
- LZB 2
- JANX 8
- Target Price
- LZB $46.00
- JANX $90.63
- AVG Volume (30 Days)
- LZB 447.2K
- JANX 876.9K
- Earning Date
- LZB 08-19-2025
- JANX 08-07-2025
- Dividend Yield
- LZB 2.28%
- JANX N/A
- EPS Growth
- LZB N/A
- JANX N/A
- EPS
- LZB 2.35
- JANX N/A
- Revenue
- LZB $2,109,207,000.00
- JANX $439,000.00
- Revenue This Year
- LZB $3.69
- JANX N/A
- Revenue Next Year
- LZB $3.43
- JANX $1,470.83
- P/E Ratio
- LZB $16.45
- JANX N/A
- Revenue Growth
- LZB 3.04
- JANX N/A
- 52 Week Low
- LZB $34.89
- JANX $21.97
- 52 Week High
- LZB $48.31
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- LZB 55.75
- JANX 53.07
- Support Level
- LZB $38.13
- JANX $23.96
- Resistance Level
- LZB $39.45
- JANX $25.93
- Average True Range (ATR)
- LZB 0.88
- JANX 1.55
- MACD
- LZB 0.34
- JANX 0.08
- Stochastic Oscillator
- LZB 82.83
- JANX 69.31
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.